Inhibrx, Inc(NASDAQ:INBX) 
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarc...
Website: http://www.inhibrx.com
Founded: 2010
Full Time Employees: 75
CEO: Mark P. Lappe
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 13.20
H 14.08
L 12.46
C 13.34
V 270,761
10EMA 13.34
20EMA 13.34
60EMA 13.34
120EMA 13.34
250EMA 13.34